At the Herbert Irving Comprehensive Cancer Center at Columbia University and NewYork-Presbyterian Hospital, we believe that our discoveries here will end cancer everywhere.
Working together, we empower innovation and discovery in prevention, research and clinical care to reduce the burden of cancer for our patients, our community, and the world.
Palliative Care Expert Provides Insight Into Best Practices
A consensus has emerged among oncology practitioners that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.
Dr. Blinderman on Early Palliative Care for Patients With Metastatic Disease
September 24th 2014Craig Blinderman, MD, Attending Physician in Medicine & Anesthesiology NewYork-Presbyterian Hospital/Columbia University Medical Center, Assistant Professor of Palliative Care (Medicine & Anesthesiology), Columbia University, discusses starting palliative care early in patients with metastatic disease.
Alpha-Particle Radiopharmaceuticals Moving Forward as AML Therapy
September 8th 2014Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.
Dr. Fine on GTX in Inoperable Pancreatic Cancer
March 5th 2014Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma
Dr. Hershman on Adherence to Longer Hormonal Therapy
August 1st 2013Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.